HIV and Inflammatory or Autoimmune Disease: Rare Patients, Many Questions (MAIVIH)

NCT05036811 | Unknown

• 1 other identifier: NRIPH_2020_11
• Study Type: observational
• Target: 400
• Locations: 1 country
• Sites: 1

Brief Summary

Follow-up registry of patients living with HIV who also have various inflammatory and autoimmune pathologies that may require immunosuppressive treatment.

Conditions

Hiv

Outcome Measures

Primary Outcomes (1)

• Number of patients living with HIV who have an inflammatory or autoimmune disease

  At the end of the study an average of 18 months

Secondary Outcomes (4)

• Number of patients on immunosuppressive treatment,

  At the end of the study an average of 18 months

• Occurrence of infectious complications

  At the end of the study an average of 18 months

• Number of patients on remission

  At the end of the study an average of 18 months

• Evolution of CD4 and HIV viral load

  At the end of the study an average of 18 months

Interventions

data collection OTHER

data collection

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients with HIV and an inflammatory or autoimmune disease

You may qualify if:

• Patient living with HIV
• Carrier of one or more of the following diseases:
• Sarcoidosis Multiple sclerosis Myasthenia gravis Crohn's disease Hemorrhagic rectocolitis Autoimmune hepatitis Arthropathic psoriasis Still's disease, other rheumatoid arthritides, juvenile polyarthritides, Rheumatoid arthritis Vasculitides: periarteritis nodosa and related conditions, other necrotizing vasculopathies (periarteritis nodosa, juvenile periarteritis, Churg-Strauss disease, polyangiitis, Kawasaki disease, Horton's disease, Wegener's disease, thrombotic microangiopathy, Takayashu syndrome, Good-Pasture's syndrome, thrombocytopenic purpura) Lupus Polymyositis or dermatopolymyositis Connectivitis (Behcet's disease, Gougerot-Sjöogren syndrome) Inflammatory spondyloarthropathies (APS, spondyloarthritis, other spondyloarthropathies)

You may not qualify if:

• Opposition of the person
• Minor patients
• Patients under judicial protection

Sponsors & Collaborators

• Tourcoing Hospital: lead

Study Sites (1)

CH Tourcoing

Tourcoing, France

RECRUITING

MeSH Terms

Conditions

Acquired Immunodeficiency Syndrome

Interventions

Data Collection

Condition Hierarchy (Ancestors)

HIV Infections; Blood-Borne Infections; Communicable Diseases; Infections; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; RNA Virus Infections; Virus Diseases; Slow Virus Diseases; Genital Diseases; Urogenital Diseases; Immunologic Deficiency Syndromes; Immune System Diseases

Intervention Hierarchy (Ancestors)

Epidemiologic Methods; Investigative Techniques; Health Care Evaluation Mechanisms; Quality of Health Care; Health Care Quality, Access, and Evaluation; Public Health; Environment and Public Health

Study Officials

• Nathalie VIGET, MD

  CH TOURCOING

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Nathalie VIGET, MD

CONTACT

0320694848; nviget@ch-tourcoing.fr

Solange TREHOUX, PhD

CONTACT

0320694280; strehoux@ch-tourcoing.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 16, 2021
• First Posted: September 8, 2021
• Study Start: June 7, 2021
• Primary Completion: December 1, 2022
• Study Completion: March 1, 2023
• Last Updated: September 8, 2021

Record last verified: 2021-04

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)